From: Soluble PD-1 aggravates progression of collagen-induced arthritis through Th1 and Th17 pathways
Group | RA | OA | HC |
---|---|---|---|
Sample size, n | 83 | 67 | 88 |
Age, yr, mean ± standard deviation | 58.30 ± 13.01 | 56.78 ± 13.98 | 55.73 ± 15.19 |
Sex, n | |||
Male | 22 | 17 | 20 |
Female | 61 | 50 | 68 |
Mean duration of disease, mo (range) | 53.27 (1–456) | 46.31 (1–323) | – |
Stages of disease, n | |||
Early RA (≤12 mo) | 30 | ||
Late RA (>12 mo) | 53 | ||
Activity of disease, n | |||
Remission (DAS28 < 2.6) | 10 | – | – |
Low (2.6 ≤ DAS28 ≤ 3.2) | 16 | – | – |
Moderate (3.2 < DAS28 ≤ 5.1) | 45 | – | – |
High (DAS28 > 5.1) | 12 | – | – |
Manifestations of disease, n | |||
Extraarticular | 23 | – | – |
Limited joint manifestations | 60 | – | – |
Drug use before study | – | – | – |